Pneumotox » Drug » Antiviral therapy/agents (direct-acting) against hepatitis C virus

Antiviral therapy/agents (direct-acting) against hepatitis C virus

1

The role of specific drug or drugs can be difficult to evaluate in those patients receiving combinatorial therapy. Please consult current list or lists of antiviral agents elsewhere at all time, as a class effect is possible if not likely

Last update : 05/02/2019

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

1

I.b Pneumonitis (ILD)

1

II.b ARDS - Acute lung injury

1

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

-

IV.d Cough (lone)

1

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

1

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

-

XI.c Pleuritic chest pain

1

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

1

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

1

XVII.f Tuberculosis, miliary

1

XIX.a BAL: An excess proportion of lymphocytes

1

XIX.b BAL: An excess proportion of neutrophils

1

XIX.c BAL: An excess proportion of eosinophils

1

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist